Literature DB >> 17164113

The changing epidemiology and natural history of hepatitis C virus infection.

Stephanie R Bialek1, Norah A Terrault.   

Abstract

Injection drug use remains the predominant mode of transmission of hepatitis C virus (HCV) infection. Growing numbers of persons who have been chronically infected with HCV for 20 or more years are coming to medical attention and are at risk for serious complications of chronic infection, including cirrhosis and hepatocellular carcinoma. Factors linked with the development of advanced fibrosis and cirrhosis include age at infection, duration of infection, heavy alcohol use, coinfections with HIV or hepatitis B virus, and male sex. Emerging risk factors for disease progression include steatosis, insulin resistance (and factors associated with the metabolic syndrome), and host genetics.

Entities:  

Mesh:

Year:  2006        PMID: 17164113     DOI: 10.1016/j.cld.2006.08.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  27 in total

1.  Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase.

Authors:  Shuanghu Liu; Cassie A Nelson; Li Xiao; Ling Lu; Punit P Seth; Darrell R Davis; Curt H Hagedorn
Journal:  Antiviral Res       Date:  2010-11-12       Impact factor: 5.970

2.  Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing.

Authors:  Manik Sharma; Saad Al Kaabi; Anil K John; Nazeeh Al Dweik; Hameed Ullah Wani; Ragesh Babu Thandassary; Moutaz F Derbala; Khalid Al Ejji; Khaleel Sultan; Fuad Pasic; Munnera Al Mohannadi; Rafae Yacoub; Mohd Tariq Butt; Rajvir Singh
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

Review 3.  In the clinic. Hepatitis C.

Authors:  Janice H Jou; Andrew J Muir
Journal:  Ann Intern Med       Date:  2008-06-03       Impact factor: 25.391

4.  Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.

Authors:  Soo Ryang Kim; Ahmed El-Shamy; Susumu Imoto; Ke Ih Kim; Yoshi-hiro Ide; Lin Deng; Ikuo Shoji; Yasuhito Tanaka; Yutaka Hasegawa; Mitsuhiro Ota; Hak Hotta
Journal:  J Gastroenterol       Date:  2012-03-24       Impact factor: 7.527

5.  Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122.

Authors:  Liang-Tzung Lin; Ryan S Noyce; Tram N Q Pham; Joyce A Wilson; Gary R Sisson; Thomas I Michalak; Karen L Mossman; Christopher D Richardson
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

6.  Hepatitis C virus infection and nonalcoholic steatohepatitis.

Authors:  Anish Patel; Stephen A Harrison
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-05

Review 7.  Viral hepatitis and pregnancy.

Authors:  Norah A Terrault; Miriam T Levy; Ka Wang Cheung; Gonzague Jourdain
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-12       Impact factor: 46.802

8.  Gender-related distribution of the interleukin-1 beta and interleukin-1 receptor antagonist gene polymorphisms in patients with end-stage liver disease.

Authors:  Elisabetta Fontanini; Annarosa Cussigh; Carlo Fabris; Edmondo Falleti; Pierluigi Toniutto; Davide Bitetto; Sara Cmet; Elisa Fumolo; Ezio Fornasiere; Sara Bignulin; David J Pinato; Rosalba Minisini; Mario Pirisi
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

9.  Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients.

Authors:  Weiping Cai; Aiping Qin; Pengle Guo; Dehong Yan; Fengyu Hu; Qiong Yang; Min Xu; Yongshui Fu; Jie Zhou; Xiaoping Tang
Journal:  J Clin Immunol       Date:  2013-01-26       Impact factor: 8.317

Review 10.  Innate immune evasion by hepatitis C virus and West Nile virus.

Authors:  Brian C Keller; Cynthia L Johnson; Andrea Kaup Erickson; Michael Gale
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-16       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.